Myelopoiesis modulation by ACE hyperfunction in kinin B1 receptor knockout mice: Relationship with AcSDKP levels

Chemico-Biological Interactions

Volumn 184, Issue 3, 2010, Pages 388-395

  Oliveira, Carlos R ^a   Paredes Gamero, Edgar J ^a   Barbosa, Christiano M V ^a   Nascimento, Fábio D ^a   Batista, Elice C ^a   Reis, Felipe C G ^a   Martins, Antonio H B ^a   Ferreira, Alice T ^a   Carmona, Adriana K ^a   Pesquero, João B ^a   Tersariol, Ivarne L S ^a   Araújo, Ronaldo C ^a   Bincoletto, Claudia ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

ACE hyperfunction; AcSDKP levels; B1KO mice; BK; Bone marrow; GM CFC

Indexed keywords

BRADYKININ B1 RECEPTOR; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; LIPOPOLYSACCHARIDE; MESSENGER RNA; SERASPENIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CELL CYCLE S PHASE; CELL POPULATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; ENZYME ACTIVITY; FLOW CYTOMETRY; HYDROLYSIS; KALLIKREIN KININ SYSTEM; MOUSE; MYELOPOIESIS; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANIMALS; BONE MARROW CELLS; CAPTOPRIL; GRANULOCYTES; KALLIKREIN-KININ SYSTEM; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELOPOIESIS; OLIGOPEPTIDES; PEPTIDYL-DIPEPTIDASE A; RECEPTOR, BRADYKININ B1; RENIN-ANGIOTENSIN SYSTEM;

ANIMALIA; MURINAE; MUS;

EID: 77949916689     PISSN: 00092797     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbi.2010.01.015     Document Type: Article

References (45)

1. Ogawa M. Differentiation and proliferation of hematopoietic stem cells. Blood 1993, 81:2844-2853.
2. Orkin S.H. Diversification of haematopoietic stem cells to specific lineages. Nat. Rev. Genet. 2000, 1:57-64.
3. Tavian M., Coulombel L., Luton D., Clemente H.S., Dieterlen-Lièvre F., Péault B. Aorta-associated CD34+ hematopoietic cells in the early human embryo. Blood 1996, 87:67-72.
4. North T., Gu T.L., Stacy T., Wang Q., Howard L., Binder M., Marín-Padilla M., Speck N.A. Cbfa2 is required for the formation of intra-aortic hematopoietic clusters. Development 1999, 126:2563-2575.
5. Orkin S.H., Zon L.I. Hematopoiesis and stem cells: plasticity versus developmental heterogeneity. Nat. Immunol. 2002, 3:323-328.
6. Cheshier S.H., Morrison S.J., Liao X., Weissman I.L. In vivo proliferation and cell cycle kinetics of long-term self-renewing hematopoietic stem cells. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:3120-3125.
7. Cheng T., Rodrigues N., Shen H., Yang Y., Dombkowski D., Sykes M., Scadden D.T. Hematopoietic stem cell quiescence maintained by p21cip1/waf1. Science 2000, 287:1804-1808.
8. Larsson J., Karlsson S. The role of Smad signaling in hematopoiesis. Oncogene 2005, 24:5676-5692.
9. Haznedaroĝlu I.C., Tuncer S., Gürsoy M. A local renin-angiotensin system in the bone marrow. Med. Hypotheses 1996, 46:507-510.
10. Strawn W.B., Richmond R.S., Tallant E.A., Gallagher P.E., Ferrario C.M. Renin-angiotensin system expression in rat bone marrow haematopoietic and stromal cells. Br. J. Haematol. 2004, 126:120-126.
11. Okamura A., Raukugi H., Ohishi M., Yanagitani Y., Takiuchi S., Moriguchi K., Fennessy P.A., Higaki J., Ogihara T. Upregulation of renin-angiotensin system during differentiation of monocytes to macrophages. J. Hypertens. 1999, 17:537-545.
12. Chisi J.E., Wdzieczak-Bakala J., Thierry J., Briscoe C.V., Riches A.C. Captopril inhibits the proliferation of hematopoietic stem and progenitor cells in murine long-term bone marrow cultures. Stem Cells 1999, 17:339-344.
13. Rodgers K.E., Xiong S., Steer R., diZerega G.S. Effect of angiotensin II on hematopoietic progenitor cell proliferation. Stem Cells 2000, 18:287-294.
14. Rieger K.J., Saez-Servent N., Papet M.P., Wdzieczak-Bakala J., Morgat J.L., Thierry J., Voelter W., Lenfant M. Involvement of human plasma angiotensin I-converting enzyme in the degradation of the haemoregulatory peptide N-acetyl-seryl-aspartyl-lysyl-proline. Biochem. J. 1993, 296:373-378.
15. Robinson S., Lenfant M., Wdzieczak-Bakala J., Melville J., Riches A. The mechanism of action of the tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (AcSDKP) in the control of haematopoietic stem cell proliferation. Cell Prolif. 1992, 25:623-632.
16. Cole J., Ertoy D., Lin H., Sutliff R.L., Ezan E., Guyene T.T., Capecchi M., Corvol P., Bernstein K.E. Lack of angiotensin II-facilitated erythropoiesis causes anemia in angiotensin-converting enzyme-deficient mice. J. Clin. Invest. 2000, 106:1391-1398.
17. Comte L., Lorgeot V., Volkov L., Allegraud A., Aldigier J.C., Praloran V. Effects of the angiotensin-converting enzyme inhibitor enalapril on blood haematopoietic progenitors and Acetyl-N-Ser-Asp-Lys-Pro concentrations. Eur. J. Clin. Invest. 1997, 27:788-790.
18. Abali H., Haznedaroĝlu I.C., Goker H., Çelik I., Özatli D., Koray Z., Çaglar M. Circulating and local bone marrow renin-angiotensin system in leukemic hematopoiesis: preliminary evidences. Hematology 2002, 7:75-82.
19. Frindel E., Guigon M. Inhibition of CFU entry into cycle by a bone marrow extract. Exp. Hematol. 1977, 5:74-76.
20. Lenfant M., Wdzieczak-Bakala J., Guittet E., Prome J.C., Sotty D., Frindel E. Inhibitor of hematopoietic pluripotent stem cell proliferation: purification and determination of its structure. Proc. Natl. Acad. Sci. U.S.A. 1989, 86:779-782.
21. Zambidis E.T., Park T.S., Yu W., Tam A., Levine M., Yuan X., Pryzhkova M., Péault B. Expression of angiotensin-converting enzyme (CD143) identifies and regulates primitive hemangioblasts derived from human pluripotent stem cells. Blood 2008, 112:3601-3614.
22. Rousseau A., Michaud A., Chauvet M.T., Lenfant M., Corvol P. The homoregulatory peptide N-acetyl-Ser-Asp-Lys-Pro is a natural and specific substrate of the N-terminal active site of human angiotensin-converting enzyme. J. Biol. Chem. 1995, 270:3656-3661.
23. Mrug M., Stopka T., Julian B.A., Prchal J.F., Prchal J.T. Angiotensin II stimulates proliferation of normal early erythroid progenitors. J. Clin. Invest. 1997, 100:2310-2314.
24. Charrier S., Michaud A., Badaoui S., Giroux S., Ezan E., Sainteny F., Corvol P., Vainchenker W. Inhibition of angiotensin I-converting enzyme induces radioprotection by preserving murine hematopoietic short-term reconstituting cells. Blood 2004, 104:978-985.
25. Moreau M.E., Garbacki N., Molinaro G., Brown N.J., Marceau F., Adam A. The kallikrein-kinin system: current and future pharmacological targets. J. Pharmacol. Sci. 2005, 99:6-38.
26. Marceau F., Hess J.F., Bachvarov D.R. The B1 receptors for kinins. Pharmacol. Rev. 1998, 50:357-386.
27. Hara D.B., Leite D.F.P., Fernandes E.S., Passos G.F., Guimarães A.O., Pesquero J.B., Campos M.M., Calixto J.B. The relevance of kinin B1 receptor upregulation in a mouse model of colitis. Br. J. Pharmacol. 2008, 154:1276-1286.
28. Austin C.E., Faussner A., Robinson H.E., Chakravarty S., Kyle D.J., Bathon J.M., Proud D. Stable expression of the human kinin B1 receptor in Chinese hamster ovary cells. Characterization of ligand binding and effector pathways. J. Biol. Chem. 1997, 272:11420-11425.
29. Mathis S.A., Criscimagna N.L., Leeb-Lundberg L.M. B1 and B2 kinin receptors mediate distinct patterns of intracellular Ca2+ signaling in single cultured vascular smooth muscle cells. Mol. Pharmacol. 1996, 50:128-139.
30. Regoli D., Barabé J. Pharmacology of bradykinin and related kinins. Pharmacol. Rev. 1980, 32:1-46.
31. Schachter M. Kallikreins (kininogenases)-a group of serine proteases with bioregulatory actions. Pharmacol. Rev. 1979, 31:1-17.
32. Duma E.M., Foster J.S., Moore R.N. Bradykinin sensitization of CSF-1-responsive murine mononuclear phagocyte precursors to prostaglandin E. J. Immunol. 1988, 141:3186-3189.
33. Chisi J.E., Briscoe C.V., Ezan E., Genet R., Riches A.C., Wdzieczak-Bakala J. Captopril inhibits in vitro and in vivo the proliferation of primitive haematopoietic cells induced into cell cycle by cytotoxic drug administration or irradiation but has no effect on myeloid leukaemia cell proliferation. Br. J. Haematol. 2000, 109:563-570.
34. Araujo M.C., Melo R.L., Cesari M.H., Juliano M.A., Juliano L., Carmona A.K. Peptidase specificity characterization of C- and N-terminal catalytic sites of angiotensin I-converting enzyme. Biochemistry 2000, 39:8519-8525.
35. Pradelles P., Frobert Y., Créminon C., Ivonine H., Frindel E. Distribution of a negative regulator of haematopoietic stem cell proliferation (AcSDKP) and thymosin beta 4 in mouse tissues. FEBS Lett. 1991, 289:171-175.
36. Crisan D., Carr J. Angiotensin I-converting enzyme: genotype and disease associations. J. Mol. Diagn. 2000, 2:105-115.
37. Kanasaki K., Haneda H., Sugimoto T., Shibuya K., Isono M., Isshiki K., Araki S., Uzu T., Kashiwagi A., Koya D. N-Acetyl-seryl-aspartyl-lysyl-proline inhibits DNA synthesis in human mesangial cells via up-regulation of cell cycle modulators. Biochem. Biophys. Res. Commun. 2006, 342:758-765.
38. Fleming I. Signaling by the angiotensin-converting enzyme. Circ. Res. 2006, 98:887-896.
39. Leeanansaksiri W., DeSimone S.K., Huff T., Hannappel E., Huff T.F. Thymosin beta 4 and its N-terminal tetrapeptide, AcSDKP, inhibit proliferation, and induce dysplastic, non-apoptotic nuclei and degranulation of mast cells. Chem. Biodivers. 2004, 1:1091-1100.
40. Wdzieczak-Bakala J., Fache M.P., Lenfant M., Frindel E., Sainteny F. AcSDKP, an inhibitor of CFU-S proliferation, is synthesized in mice under steady-state conditions and secreted by bone marrow in long-term culture. Leukemia 1990, 4:235-237.
41. Bogden A.E., Carde P., de Paillette E.D., Moreau J.P., Tubiana M., Frindel E. Amelioration of chemotherapy-induced toxicity by cotreatment with AcSDKP, a tetrapeptide inhibitor of hematopoietic stem cell proliferation. Ann. N. Y. Acad. Sci. 1991, 628:126-139.
42. Massé A., Ramirez L.H., Bindoula G., Grillon C., Wdzieczak-Bakala J., Raddassi K., Deschamps de Paillette E., Mencia-Huerta J.M., Koscielny S., Potier P., Sainteny F., Carde P. The tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (Goralatide) protects from doxorubicin-induced toxicity: improvement in mice survival and protection of bone marrow stem cells and progenitors. Blood 1998, 91:441-449.
43. Watanabe T., Brown G.S., Kelsey L.S., Yan Y., Jackson J.D., Ewel C., Kessinger A., Talmadge J.E. In vivo protective effects of tetrapeptide AcSDKP, with or without granulocyte colony-stimulation factor, on murine progenitor cells after sublethal irradiation. Exp. Hematol. 1996, 24:713-721.
44. Carde P., Chastang C., Goncalves E., Mathieu-Tubiana N., Vuillemin E., Delwail V., Corbion O., Vekhoff A., Isnard F., Ferrero J.M., Garcia-Giralt E., Gimonet J.F., Stoppa A.M., Léger-Picherit E., Fadel E., Monpezat J.P., Munck J.N., Domenge C., Khayat D., Guilhot F. Séraspénide (acétyl SDKP): étude en phases I-II d'un inhibiteur de l'hématopoièse la protégeant de la toxicité de monochimiothérapies aracytine et ifosfamide. C. R. Acad. Sci. 1992, 315:545-550.
45. Sabatini R.A., Guimarães P.B., Fernandes L., Reis F.C., Bersanetti P.A., Mori M.A., Navarro A., Hilzendeger A.M., Santos E.L., Andrade M.C., Chagas J.R., Pesquero J.L., Casarini D.E., Bader M., Carmona A.K., Pesquero J.B. ACE activity is modulated by kinin B2 receptor. Hypertension 2008, 51:689-695.